A Study Using Botulinum Toxin Type A as Headache Prophylaxis in Adolescents With Chronic Migraine
Trial status: Open for Enrollment
Why is this study being done?
To evaluate the efficacy and safety of Botulinum Toxin Type A versus placebo (normal saline) as headache prophylaxis in adolescents (children 12 to 17) with chronic migraine.
Who is eligible to participate?
- Medical history of chronic migraine for at least 6 months
- 15 or more headache days during a 4 week period
- Previous use of any botulinum toxin of any serotype for any reason
- Diagnosis of Myasthenia gravis, Eaton-Lambert Syndrome, Amyotrophic Lateral Sclerosis
- Treatment of headache using acupuncture, transcutaneous electrical stimulation (TENS), cranial traction, dental splints, or injection of anesthetics/steroids within 4 weeks prior to the week -4 screening visit
- Use of any headache prophylaxis medication within 4 weeks prior to the week -4 screening visit